Esquizofrenia de inicio en la infancia/adolescencia y respuesta a psicofármacos:un binomio complejo

  1. Antía Diéguez Quintairos 1
  2. María Dolores Domínguez Santos 1
  3. José Mazaira Castro 1
  4. Lucía Varela Reboiras 1
  5. Lucía del Río Casanova 1
  1. 1 Complexo Hospitalario de Santiago de Compostela, Santiago de Compostela, A Coruña
Journal:
Revista de Psiquiatría Infanto-Juvenil

ISSN: 2660-7271,  1130-9512

Year of publication: 2015

Volume: 32

Issue: 1

Pages: 67-69

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista de Psiquiatría Infanto-Juvenil

Abstract

Early onset schizophrenia (EOS-under 15 years-) and very early onset schizophrenia (VEOS-under 13 years-) is a rare condition (12-33% and 1% of all cases respectively) which continues with adult schizophrenia, but has a worse prognosis due to associating more varied symptoms and a poorer response to psychopharmacological treatment (first-line drugs fail in 50% of patients, considering at this age, too, clozapine as third line treatment in refractory cases).

Bibliographic References

  • Castro-Fornieles J, Parellada M, Soutullo CA, et al. Antipsychotic treatment in child and adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. J Child Adolesc Psychopharmacol 2008; 18: 327-36.
  • Fourneret P, Georgieff N, Franck N. Early onset schizophrenia: Current data and therapeutic approach. Arch Pediatr 2013; 20 (7): 789-99.
  • Clinical practice guideline for schizophrenia and incipient psychotic disorder. Clinical practice guideline: CAHTA; no. 2006/05-2.
  • Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother 2008; 9 (3): 459-465.
  • Actualización en esquizofrenia ultrarresistente al tratamiento. Cap.11: Potenciación de la clozapina con antipsicóticos atípicos: Amisulpride. Coord: Espiño Díaz I, Ramos Ríos R.
  • Tufan A, Yalug I. Clozapine augmented with amisulpride in 3 cases of Treatment –Resistant Early-and Very Early-Onset Schizophrenia. J Clin Psychopharmacol 2013; 33: 572-574.
Data source: Dialnet